NASDAQ:OMCL - Nasdaq - US68213N1090 - Common Stock - Currency: USD
Shares of healthcare tech company Omnicell (NASDAQ:OMCL) jumped 5.9% in the afternoon session after the company reported impressive preliminary second quarter 2025 and full-year profit guidance due to reduced tariffs on imports in China.
Healthcare tech company Omnicell (NASDAQ:OMCL) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 9.6% year on year to $269.7 million. On the other hand, next quarter’s revenue guidance of $275 million was less impressive, coming in 0.7% below analysts’ estimates. Its non-GAAP profit of $0.26 per share was 27.1% above analysts’ consensus estimates.
Coinbase Global shares fell on Thursday after the crypto exchange said a recent cyberattack that breached customer account data could cost up the company up to $400 million.
Take-Two beat expectations for revenue in the fourth quarter, but large impairment charges pushed the bottom line deep into the red. Revenue and net bookings grew by double-digit percentages, and the company expects both metrics to grow in fiscal 2026. The company won't get a major boost to sales from Grand Theft Auto VI until fiscal 2027.
OMCL unveils new offerings for the perioperative and clinic setting.
OMCL posts better-than-expected top and bottom-line results for the first quarter of 2025.
Omnicell (OMCL) delivered earnings and revenue surprises of 62.50% and 4.24%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: PIII
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.